Öz
Kaynakça
- 1. Saran R, Robinson B, Abbott KC, Agodoa LYC, Bragg-Gresham J, Balkrishnan R, et al. US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2019;73(3 Suppl 1):A7-A8
- 2. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260-72.
- 3. Yokota N, Takahashi M, Nishitani M, Minakuchi J, Kanayama HO. Long-term outcomes of the Japanese hemodialysis patients with prostate cancer detected by prostate-specific antigen screening. J Med Invest. 2021;68(1.2):42-47.
- 4. Kensler KH, Rebbeck TR. Cancer Progress and Priorities: Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2020;29(2):267-277.
- 5. GLOBOCAN 2020: New Global Cancer Data. Available from: https://gco.iarc.fr/today/data/factsheets/populations/792-turkey-fact-sheets.pdf. Accessed: January 2021
- 6. Birkenmeier G, Struck F, Gebhardt R. Clearance mechanism of prostate specific antigen and its complexes with alpha2-macroglobulin and alpha1- antichymotrypsin. J Urol. 1999;162:897–901.
- 7. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTROSIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017;71(4):618-629.
- 8. Sasagawa I, Kubota Y, Hayami S, Adachi M, Nakada T, Miura H, et al. Serum levels of total and free prostate specific antigen in men on hemodialysis. J Urol. 1998;160:83–85.
- 9. Horinaga M, Kitamura K, Saito S, Ukimura O, Nakanoma T, Okihara K, et al. Prostate cancer screening with prostate-specific antigen in hemodialysis patients. Urol Int. 2007;78(4):334-7.
- 10. Tzanakis I, Kazoulis S, Girousis N, Kagia S, Spandidakis V, Karefillakis N, et al. Prostate-specific antigen in hemodialysis patients and the influence of dialysis in its levels. Nephron. 2002;90(2):230-3.
- 11. Wolff JM, Ting O, Borchers H, Rohde D, Jakse G. Serum levels of prostate-specific antigen in men on hemodialysis. Anticancer Res. 2000;20:5191–5193.
- 12. Maoujoud O, El Machtani S, Asseraji M, Atbib Y, Zajjari Y, Taoufik A, et al. Serum tumor markers in hemodialysis patients. Int J Artif Organs. 2014;37(2):126-32.
- 13. Kabalin JN, and Hornberger JC. Prostatic specific antigen is not excreted by human kidney or eliminated by routine hemodialysis. 1991;37(4):308-10.
- 14. Monath JR, Burkart JM, Freedman BI, Pittaway DE, Russell GB, Assimos DG. Effects of hemodialysis on prostate-specific antigen. Urology. 1993;42(4):398-400.
- 15. Bruun L, Savage C, Cronin AM, Hugosson J, Lilja H, Christensson A. Increase in percent free prostate-specific antigen in men with chronic kidney disease. Nephrol Dial Transplant. 2009;24(4):1238-41.
- 16. Aminsharifi A, Simon R, Polascik TJ, et al. Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer. J Urol. 2019;202(3):469-474.
- 17. Bruun L, Björk T, Lilja H, Becker C, Gustafsson O, Christensson A. Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment. Nephrol Dial Transplant. 2003;18(3):598-603.
The Change in tPSA, fPSA and f/tPSA Levels in Men Undergoing Hemodialysis Effect of Hemodialysis on Serum PSA Levels
Öz
Purpose: This study aimed to assess the impact of hemodialysis treatment and different dialysis membranes with varying surface areas on serum levels of total prostate-specific antigen (tPSA), free prostate-specific antigen (fPSA), and the fPSA/tPSA ratio in patients undergoing hemodialysis treatment.
Material and Methods: The study was conducted at the Central Laboratory of....Hospital in May, June, and July 2020. tPSA, fPSA, and fPSA/tPSA ratios measured in pre-dialysis and post-dialysis samples were determined. Correlation between pre-dialysis and post-dialysis of fPSA and tPSA levels and patients' ultrafiltrates were evaluated. The fPSA, tPSA, and fPSA/tPSA measured in pre-dialysis and post-dialysis samples grouped according to membrane type were compared.
Results: The fPSA levels and fPSA/tPSA ratios of pre-dialysis samples were significantly lower than post-dialysis samples. tPSA values were not significantly different in pre-dialysis and post-dialysis samples. According to membrane types, it was found that pre-dialysis and post-dialysis tPSA, fPSA, and fPSA/tPSA were not significantly different. There was a positive correlation between difference in fPSA concentrations measured in pre-dialysis and post-dialysis samples and ultrafiltrate (rho=0.380). A positive correlation was found between difference in tPSA concentrations measured in pre-dialysis and post-dialysis samples and ultrafiltrate (rho=0.562).
Conclusion: Post-dialysis fPSA values and fPSA/tPSA ratios were found to be elevated in patients receiving hemodialysis treatment due to hemoconcentration and other potential effects of dialysis. Therefore, interpreting fPSA values and fPSA/tPSA ratios in patients undergoing hemodialysis treatment according to current clinical decision limits may lead to misinterpretation. In this group of patients, the use of tPSA testing is safe as it remains unaffected by dialysis treatment.
Anahtar Kelimeler
Prostate Specific Antigen Biological Tumour Markers Dialysis
Kaynakça
- 1. Saran R, Robinson B, Abbott KC, Agodoa LYC, Bragg-Gresham J, Balkrishnan R, et al. US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2019;73(3 Suppl 1):A7-A8
- 2. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260-72.
- 3. Yokota N, Takahashi M, Nishitani M, Minakuchi J, Kanayama HO. Long-term outcomes of the Japanese hemodialysis patients with prostate cancer detected by prostate-specific antigen screening. J Med Invest. 2021;68(1.2):42-47.
- 4. Kensler KH, Rebbeck TR. Cancer Progress and Priorities: Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2020;29(2):267-277.
- 5. GLOBOCAN 2020: New Global Cancer Data. Available from: https://gco.iarc.fr/today/data/factsheets/populations/792-turkey-fact-sheets.pdf. Accessed: January 2021
- 6. Birkenmeier G, Struck F, Gebhardt R. Clearance mechanism of prostate specific antigen and its complexes with alpha2-macroglobulin and alpha1- antichymotrypsin. J Urol. 1999;162:897–901.
- 7. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTROSIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017;71(4):618-629.
- 8. Sasagawa I, Kubota Y, Hayami S, Adachi M, Nakada T, Miura H, et al. Serum levels of total and free prostate specific antigen in men on hemodialysis. J Urol. 1998;160:83–85.
- 9. Horinaga M, Kitamura K, Saito S, Ukimura O, Nakanoma T, Okihara K, et al. Prostate cancer screening with prostate-specific antigen in hemodialysis patients. Urol Int. 2007;78(4):334-7.
- 10. Tzanakis I, Kazoulis S, Girousis N, Kagia S, Spandidakis V, Karefillakis N, et al. Prostate-specific antigen in hemodialysis patients and the influence of dialysis in its levels. Nephron. 2002;90(2):230-3.
- 11. Wolff JM, Ting O, Borchers H, Rohde D, Jakse G. Serum levels of prostate-specific antigen in men on hemodialysis. Anticancer Res. 2000;20:5191–5193.
- 12. Maoujoud O, El Machtani S, Asseraji M, Atbib Y, Zajjari Y, Taoufik A, et al. Serum tumor markers in hemodialysis patients. Int J Artif Organs. 2014;37(2):126-32.
- 13. Kabalin JN, and Hornberger JC. Prostatic specific antigen is not excreted by human kidney or eliminated by routine hemodialysis. 1991;37(4):308-10.
- 14. Monath JR, Burkart JM, Freedman BI, Pittaway DE, Russell GB, Assimos DG. Effects of hemodialysis on prostate-specific antigen. Urology. 1993;42(4):398-400.
- 15. Bruun L, Savage C, Cronin AM, Hugosson J, Lilja H, Christensson A. Increase in percent free prostate-specific antigen in men with chronic kidney disease. Nephrol Dial Transplant. 2009;24(4):1238-41.
- 16. Aminsharifi A, Simon R, Polascik TJ, et al. Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer. J Urol. 2019;202(3):469-474.
- 17. Bruun L, Björk T, Lilja H, Becker C, Gustafsson O, Christensson A. Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment. Nephrol Dial Transplant. 2003;18(3):598-603.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Klinik Tıp Bilimleri |
| Bölüm | Research Article |
| Yazarlar | |
| Erken Görünüm Tarihi | 8 Haziran 2023 |
| Yayımlanma Tarihi | 10 Temmuz 2023 |
| Gönderilme Tarihi | 1 Eylül 2022 |
| Yayımlandığı Sayı | Yıl 2023Cilt: 14 Sayı: 3 |
